Neurofibromatosis type 1 is a common (1 in 3500) nerve disorder that is identified at a very young age. A misfunctioning gene on chromosome 17 produces non-functional neurofibromin – a key tumor suppressor.
As well as developing neurofibromas and a range of other effects, NF1 patients have a higher predisposition for cancer development. Current treatments provide limited symptom management.
Parkinson’s disease will touch many lives with an ageing global population. The functional loss of dopaminergic neurons and wider progressive neurodegeneration has long been a target for researchers.
Changing the levels of the ‘prion-like’ protein alpha synuclein has shown benefits in cell and in vivo PD models – however translation to humans has been held back by poor delivery platforms.
Parkinson’s disease will touch many lives with an ageing global population. The functional loss of dopaminergic neurons and wider progressive neurodegeneration has long been a target for researchers.
Changing the levels of the ‘prion-like’ protein alpha synuclein has shown benefits in cell and in vivo PD models – however translation to humans has been held back by poor delivery platforms.
Neurofibromatosis type 1 is a common (1 in 3500) nerve disorder that is identified at a very young age. A misfunctioning gene on chromosome 17 produces non-functional neurofibromin – a key tumor suppressor.
As well as developing neurofibromas and a range of other effects, NF1 patients have a higher predisposition for cancer development. Current treatments provide limited symptom management.
TargoPep Ltd., Suite 2, Orchard Brae House, 30 Queensferry Road, Edinburgh EH4 2HS, United Kingdom
info@targopep.com
TargoPep Ltd. is a company registered in Scotland SC715354 | All content © 2024 TargoPep Ltd.